Phase II trials with an antisense oligonucleotide against HSP-27 in CRPC are underway.

以HSP-27为靶点的反义寡核甘酸正处于第二期临床试验中。

The objective of this study was to determine whether men with CRPC who had higher pain interference scores at baseline had worse clinical outcomes compared with men who had lower pain scores.

本研究的目的是评价是否CRPC男性而合并较高疼痛评分的患者其临床结果差于疼痛评分低分者。